Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
The presentation schedule of selected abstracts is as follows:
Abstract #689 "Oncogenic H-ras facilitates apoptosis induced by histone deacetylase inhibitors in human urinary bladder cancer cells" will be presented in a poster session Sunday, April 15 from 8:00 am - 12:00 pm. Dr. Shambhunath Choudhary et al of the University of Tennessee are authors.
Abstract #1835 "The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphomocytic leukemia (CLL) cells in association with NF-kB inactivation" will be presented in a poster session on Monday, April 16 from 8:00 am - 12:00 pm. Dr. Yun Dai et al of the Virginia Commonwealth University and Massey Cancer Center are authors.
Abstract #2484 "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" will be presented in an oral session on Monday April 16 from 11:55 am - 12:10 pm. Dr. Wei Zhang et al of the UT Southwestern Medical Center are authors.
Abstract #3524 "Translational studies of depsipeptide (romidepsin, FK228) a histone deacetylase (HDAC) inhibitor, in patients with head and neck cancer" will be presented in a poster session on Tuesday April 17 from 8:00 am - 12:00 pm. Dr. Missak Haigentz Jr. et al of the Albert Einstein College of Medicine, the Dana-Farber Cancer Institute and National Cancer Institute/CTEP are authors.
Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL). Romidepsin has received Orphan Drug Designation from the Food and Drug Administration (FDA) for the treatment of non-Hodgkin T-cell lymphomas, which includes CTCL and PTCL. In addition, the European Agency for the Evaluation of Medicinal Products (EMEA) has issued Orphan Drug status for the treatment of both CTCL and PTCL. Fast Track status for CTCL has also been designated by the FDA. Romidepsin is in clinical trials for a variety of other hematological malignancies and solid tumors, including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with the Company.
About Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-474-2825.
Posted: April 2007